Fredun Pharmaceuticals Limited has announced a significant addition to its leadership team. The company's Board of Directors has appointed Ms. Daisy Cyril Dsouza as an Additional Independent Director, following the recommendation of the Nomination & Remuneration Committee.

Key Details of the Appointment

• Term: Five years, from November 24, 2023 to November 23, 2028
• Position: Additional Independent Director
• Approval: Board of Directors, based on Nomination & Remuneration Committee recommendation

About Daisy Cyril Dsouza

Ms. Dsouza brings a wealth of experience and academic credentials to her new role:

• Education: Master's in Commerce from University of Mumbai (1995)
• Banking Experience:
  • Mandvi Bank: 12-13 years (since 1996)
  • Saraswat Bank: Approximately 12 years (since 2007)

Independence and Compliance

The company has emphasized that Ms. Dsouza:

• Is not related to any Director, Key Managerial Personnel, or Promoters of Fredun Pharmaceuticals Limited
• Is not debarred from holding directorial positions

This appointment aligns with corporate governance best practices, ensuring independence in the board's composition.

The addition of Ms. Dsouza to the board is expected to bring fresh perspectives and valuable insights, particularly given her extensive experience in the banking sector. Her appointment may contribute to strengthening Fredun Pharmaceuticals' financial strategies and corporate governance framework.

Fredun Pharmaceuticals Limited has reported a robust financial performance for the first quarter, with significant growth across key metrics. The company also announced the appointment of two new independent directors to its board.

Strong Financial Performance

The Mumbai-based pharmaceutical company saw its net profit soar by 64% year-over-year to ₹6.77 crore in Q1, compared to ₹4.13 crore in the same period last year. This impressive growth was accompanied by a 52% increase in total income, which reached ₹119.86 crore.

Fredun Pharmaceuticals' EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) grew by 62% to ₹16.99 crore, with the EBITDA margin improving to 14.18% from 13.30% in the previous year. The company's diluted earnings per share (EPS) also saw a significant rise of 63% to ₹14.33.

Key Financial Highlights

Business Expansion and Order Book

Fredun Pharmaceuticals, which operates across generics, cosmeceuticals, nutraceuticals, mobility aids, and animal healthcare products, reported having over 1,200 products under registration. The company maintains a strong order book exceeding ₹200 crore, providing solid revenue visibility for upcoming quarters.

During the quarter, the company's subsidiary acquired a controlling stake in One Pet Stop, marking its entry into the organized pet care market. This strategic move is expected to expand Fredun's pet care business.

Credit Rating Upgrade

The company received a credit rating upgrade to IVR BBB/Stable from IVR BBB-/Stable for facilities totaling ₹139.64 crore. This upgrade reflects the company's improving financial profile and business prospects.

Board Appointments

In addition to the financial results, Fredun Pharmaceuticals announced the appointment of two new independent directors to its board:

1. Mr. Anshu Agarwal (DIN: 11206436): A Chartered Accountant and Certified Public Accountant with expertise in financial accounting, analytics, and auditing.

2. Ms. Sonal Desai (DIN: 11167642): A Company Secretary with extensive knowledge in corporate laws, governance, and compliance.

Both appointments are for a term of five years, effective July 30, 2025, subject to shareholder approval.

As Fredun Pharmaceuticals continues to strengthen its market position and diversify its product portfolio, the company appears well-positioned for sustained growth in the dynamic pharmaceutical and healthcare sectors.